DE59309388D1 - Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung - Google Patents

Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Info

Publication number
DE59309388D1
DE59309388D1 DE59309388T DE59309388T DE59309388D1 DE 59309388 D1 DE59309388 D1 DE 59309388D1 DE 59309388 T DE59309388 T DE 59309388T DE 59309388 T DE59309388 T DE 59309388T DE 59309388 D1 DE59309388 D1 DE 59309388D1
Authority
DE
Germany
Prior art keywords
production
solid pharmaceutical
protracted
pharmaceutical tablets
stage release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59309388T
Other languages
English (en)
Inventor
Eberhard Prof Dr Nuernberg
Ehrhard Dr Seiller
Stefan Ritsert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz and Co GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz and Co GmbH and Co KG filed Critical Merz and Co GmbH and Co KG
Priority to DE59309388T priority Critical patent/DE59309388D1/de
Application granted granted Critical
Publication of DE59309388D1 publication Critical patent/DE59309388D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE59309388T 1992-08-04 1993-07-28 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung Expired - Lifetime DE59309388D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE59309388T DE59309388D1 (de) 1992-08-04 1993-07-28 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4225730A DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
DE59309388T DE59309388D1 (de) 1992-08-04 1993-07-28 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Publications (1)

Publication Number Publication Date
DE59309388D1 true DE59309388D1 (de) 1999-04-01

Family

ID=6464804

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4225730A Expired - Lifetime DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
DE59309388T Expired - Lifetime DE59309388D1 (de) 1992-08-04 1993-07-28 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE4225730A Expired - Lifetime DE4225730C2 (de) 1992-08-04 1992-08-04 Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung

Country Status (17)

Country Link
US (1) US5382601A (de)
EP (1) EP0582186B1 (de)
JP (1) JP3560244B2 (de)
CN (1) CN1086708A (de)
AT (1) ATE176866T1 (de)
AU (1) AU669731B2 (de)
CA (1) CA2141691C (de)
DE (2) DE4225730C2 (de)
DK (1) DK0582186T3 (de)
ES (1) ES2128369T3 (de)
GR (1) GR3030227T3 (de)
IL (1) IL106580A (de)
LT (1) LT3201B (de)
LV (1) LV10182B (de)
MX (1) MX9304675A (de)
WO (1) WO1994003158A1 (de)
ZA (1) ZA935614B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
AU3860797A (en) * 1997-07-16 1999-02-10 Antrin Research Limited Pharmaceutical formulations for oral administration
US5980941A (en) * 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
US5840334A (en) * 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5952389A (en) * 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
DE19809242A1 (de) * 1998-03-05 1999-09-09 Basf Ag Verfahren zur Herstellung von festen, sphärischen Formkörpern, enthaltend pharmazeutische Wirkstoffe in einer Bindemittelmatrix
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1852113A3 (de) * 2000-12-07 2008-03-12 Neuromolecular Inc. Verfahren zur Behandlung neuropsychiatrischer Erkrankungen mit NMDA-Rezeptorantagonisten
EP1715843A1 (de) * 2004-01-29 2006-11-02 Neuromolecular Inc. Kombination eines nmda-rezeptor-antagonisten und eines mao-hemmers oder eines gadph-hemmers zur behandlung von erkrankungen im zusammenhang mit dem zentralen nervensystem
WO2005079773A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
JP2007522249A (ja) * 2004-02-13 2007-08-09 ニューロモレキュラー・インコーポレイテッド 精神医学的状態の処置のための、ｎｍｄａレセプターアンタゴニストと、抗うつ薬であるｍａｏインヒビターまたはｇａｄｐｈインヒビターとの併用
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
KR100901927B1 (ko) * 2004-06-17 2009-06-10 메르츠 파마 게엠베하 운트 코. 카가아 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
EP1765287A2 (de) 2004-06-17 2007-03-28 Merz Pharma GmbH & Co. KGaA Formulierungen für die sofortige freisetzung oraler memantin-darreichungsformen
AU2005265031A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
EP2343057A1 (de) * 2004-11-23 2011-07-13 Neuromolecular Pharmaceuticals, Inc Verfahren und Zusammensetzung zur Verabreichung eines NMDA-Rezeptorantagonisten an eine Person
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
CA2588296A1 (en) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) * 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20060160852A1 (en) * 2004-12-27 2006-07-20 Eisai Co. Ltd. Composition containing anti-dementia drug
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
WO2006118265A1 (ja) * 2005-04-28 2006-11-09 Eisai R & D Management Co., Ltd. 抗痴呆薬を含有する組成物
US20060286167A1 (en) * 2005-05-02 2006-12-21 Jane Staunton Compositions and methods for the treatment of neurodegenerative diseases
CA2607600A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
DK1966611T3 (da) * 2005-12-23 2012-09-10 Alk Abello As Fremgangsmåde til opløsningstest af farmaceutiske produkter
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
US20080067108A1 (en) * 2006-09-14 2008-03-20 Halliburton Energy Services, Inc. Methods and compositions for thermally treating a conduit used for hydrocarbon production or transmission to help remove paraffin wax buildup
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
US20080182908A1 (en) * 2007-01-25 2008-07-31 Vinita Umashankar Vyas Pharmaceutical compositions comprising memantine
EP2583669A1 (de) 2007-10-10 2013-04-24 Rubicon Research Private Limited Im Mund zerfallende Tabletten aus Memantin-Hydrochlorid mit maskiertem Geschmack
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
US8741343B2 (en) 2009-12-02 2014-06-03 Adamas Pharmaceuticals, Inc. Method of administering amantadine prior to a sleep period
EP2363119A1 (de) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Neue pharmazeutische Zusammensetzung, die zur Behandlung von Patienten mit neurodegenerativen oder neurovaskulären Erkrankungen geeignet ist
WO2012101653A2 (en) 2011-01-25 2012-08-02 Cadila Healthcare Limited Modified release pharmaceutical compositions memantine
US20130323309A1 (en) 2011-02-17 2013-12-05 Lupin Limited Sustained Release Composition of Memantine
TR201104108A2 (tr) 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
FR2980973B1 (fr) * 2011-10-11 2013-11-15 Univ Clermont Auvergne Composition pour le traitement prophylactique de la douleur neuropathique.
US20130274342A1 (en) * 2012-04-12 2013-10-17 Cerecor, Inc. Compositions and methods for treating cough
ES2623176T3 (es) 2012-08-16 2017-07-10 Teva Pharmaceutical Industries Ltd. Composición farmacéutica de memantina
WO2014122077A1 (de) * 2013-02-08 2014-08-14 Basf Se Herstellung von anorganisch-organischen kompositmaterialien durch reaktive sprühtrocknung
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2019040748A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc AMANTADINE COMPOSITIONS, THEIR PREPARATION, AND METHODS OF USE
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US11602507B2 (en) 2019-05-27 2023-03-14 Trikona Pharmaceuticals Pvt. Ltd Extended release oral composition of memantine or its salt and its process for the preparation
CU20200087A7 (es) 2020-11-24 2022-07-08 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB715874A (en) * 1952-10-03 1954-09-22 Horlicks Ltd A tablet for use in treating peptic ulcers
GB840091A (en) * 1955-09-08 1960-07-06 Upjohn Co Improvements in or relating to therapeutic compositions and the manufacture thereof
US3594467A (en) * 1968-10-09 1971-07-20 Richardson Merrell Inc Long-lasting troche
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
US4076846A (en) * 1974-11-22 1978-02-28 Sumitomo Bakelite Company Limited Protein-starch binary molding composition and shaped articles obtained therefor
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4419369A (en) * 1980-09-22 1983-12-06 Baylor College Of Medicine Protein mineral dietary module
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4913906B1 (en) * 1985-02-28 2000-06-06 Yissum Res Dev Co Controlled release dosage form of valproic acid
EP0211294A3 (de) * 1985-08-06 1988-11-17 Eltech Systems Corporation Behandlungsmittel für Flüssigkeiten
US4897380A (en) * 1985-08-30 1990-01-30 Pollack Robert L Method and composition for relieving dietary-related disorders
US4853377A (en) * 1985-10-15 1989-08-01 Pollack Robert L Method and composition for increasing production of serotonin
DK179687D0 (da) * 1987-04-08 1987-04-08 Farma Food As Praeparat
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
EP0392059B1 (de) * 1989-04-14 1993-09-15 Merz & Co. GmbH & Co. Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie
JP2571874B2 (ja) * 1989-11-06 1997-01-16 アルカーメス コントロールド セラピューティクス，インコーポレイテッド タンパク質マイクロスフェア組成物
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
AU7991191A (en) * 1990-05-23 1991-12-10 Southwest Research Institute Filament system for delivering a medicament and method
FR2664499B1 (fr) * 1990-07-16 1994-11-04 Jacques Dubois Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.

Also Published As

Publication number Publication date
ES2128369T3 (es) 1999-05-16
US5382601A (en) 1995-01-17
LV10182A (lv) 1994-10-20
CA2141691A1 (en) 1994-02-17
DE4225730A1 (de) 1994-02-10
LV10182B (en) 1995-04-20
JPH07509479A (ja) 1995-10-19
DK0582186T3 (da) 1999-09-27
EP0582186A1 (de) 1994-02-09
CA2141691C (en) 2002-04-09
ATE176866T1 (de) 1999-03-15
ZA935614B (en) 1995-02-03
GR3030227T3 (en) 1999-08-31
AU4706993A (en) 1994-03-03
IL106580A (en) 1998-02-08
AU669731B2 (en) 1996-06-20
LT3201B (en) 1995-03-27
LTIP839A (lt) 1994-08-25
EP0582186B1 (de) 1999-02-24
CN1086708A (zh) 1994-05-18
DE4225730C2 (de) 2003-04-30
IL106580A0 (en) 1993-12-08
JP3560244B2 (ja) 2004-09-02
MX9304675A (es) 1994-03-31
WO1994003158A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
DE59309388D1 (de) Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
CA2011637A1 (en) Compositions for the sustained-release of chlorhexidine
HRP20010243B1 (en) Compositions containing diphosphonic acids
CA2211381A1 (en) Compounds with growth hormone releasing properties
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
IL102591A (en) Compositions for the sustained and controlled release of peptide medicaments and their preparation
CA2124677A1 (en) Immunopotentiatory agents and physiologically acceptable salts thereof
ES2077023T3 (es) Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
ES2113040T3 (es) Procedimiento de un solo recipiente para la fabricacion de derivados del acido 3-quinoloncarboxilico.
ATE150081T1 (de) Wasserlöslicher, wasserenthärtender builder
CO5540367A2 (es) Composicion de liberacion controlada y metodo para producirla
ATE254922T1 (de) Pharmazeutische zusammensetzungen mit antimikrobieller wirkung
FI914409A (fi) Kalciumupptagande inhibitorer.
EP0173664A3 (de) Biologisch aktive Benzimidazolderivate und Verfahren zu ihrer Herstellung
ES2174930T3 (es) Composiciones de metronidazol de liberacion modificada y metodos para preparar y utilizar las mismas.
DK0443848T3 (da) Nyt antiulcermiddel
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
DE69114635D1 (de) 1,3-Diphenyl-2-propin-1-one.
EP0480391A3 (en) Emulsion-free emulsion polymers, their production and their use in sustained-release pharmaceutical compositions
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
AR008764A1 (es) Sales hidratadas de n,n'-diacetilcistina, proceso para su preparacion, y composiciones terapeuticas que comprenden a dichas sales como ingredienteactivo.
FI914410A0 (fi) Kalciumupptagande inhibitorer.
UA37211C2 (uk) Похідні 1,4-дигідропіридину у формі рацемату або енантіомерів, 2-хлор-3-ціанобензальдегід як проміжний продукт для їх одержання та фармацевтична композиція, що має антагоністичну активність по відношенню до катіонів кальцію
ATE118152T1 (de) Pestizide zusammensetzung.
GT198800030A (es) Un producto para la preparacion de un azol.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERZ PHARMA GMBH & CO. KGAA, 60318 FRANKFURT, DE